Outlook Therapeutics Inc (OTLK)

[thermo]

Two observations:

1. It's fairly common for clinical stage life science companies to rally into approvals, so long as they are reasonably likely. My view is approval is highly likely but ...
after talking with several sell side analysts, there seems to be significant skepticism among institutions. In short, many didn't like the trial design where comparisons were vs dosing schedule that is atypical currently (though this dosing schedule was an approved regimen). I add this "skepticism" color just to be sure folks understand both sides.

2. On May 15, 2023 OTLK terminated its at-the-market offering agreement, with H.C. Wainwright, moving it to BTIG. Could it be the HCW affiliated hedge funds comprise much of the large short position?

Market Date 5/19/2023
Short Interest (Shares) 16,888,787
Days to Cover 27.96
Shares Outstanding (MM Shares) 256.67
Short Interest % SO 6.58
Float (MM Shares) 124.55
Float less SI (MM Shares) 107.66
Short Interest % Float 13.56

I'm very long the stock, having added in the Dec 2022 deal.